At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 7,141 enrolled
Drug / intervention
Nesiritide +1 moredrug
Likely dose
Nesiritide 0.01 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF)
In Brief
A Phase 3 clinical trial evaluating Nesiritide and Placebo for Heart Decompensation. Completed, enrolled 7,141 participants across 328 sites in 28 countries.
Detailed Summary
The purpose of this study is to find out if nesiritide (a human B-type natriuretic peptide/hBNP) as compared to placebo, plus the usual treatment for acute decompensated heart failure, helps to improve breathing difficulties, reduce heart failure readmissions to hospitals, and helps patients live longer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Decompensation
CountriesArgentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Colombia, France, Germany, Greece, India, Israel, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Russia, Singapore, South Korea, Sweden, Taiwan, Thailand, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedMay 2007
Primary CompletionMar 2011
TodayJul 2026
First PostedMay 21, 2007
Enrollment StartMay 1, 2007
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 19.1 years ago
Interventions
Nesiritidedrug
0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
Placebodrug
matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs